LABSCO Enters An Exclusive Partnership With BioFire Diagnostics, Inc

LABSCO expands its best-in-class clinical diagnostics portfolio with access to BioFire FilmArray^® product line in specified laboratories in the 48 contiguous United States

LOUISVILLE, Ky.--(BUSINESS WIRE)--LABSCO, the leading specialty sales agent of innovative laboratory technologies and products to hospitals, physician office laboratories and alternate healthcare settings, is proud to announce that effective May 01, 2015, it will serve BioFire Diagnostics, a molecular biology affiliate of bioMérieux, a world leader in the field of in vitro diagnostics, as an exclusive sales agent partner in specified labs in the 48 contiguous United States. Market segments covered by LABSCO will be small hospital laboratories and physician office laboratories as the FilmArray system is certified CLIA moderate complexity. LABSCO will be responsible for selling, account management, local marketing and contract presentation/execution for transition contracts and new contracts.

“With this strategic partnership, BioFire has placed its confidence in LABSCO’s capabilities, which combines national reach with best-in-class technology, operational excellence and unmatched technical sales expertise”

“With this strategic partnership, BioFire has placed its confidence in LABSCO’s capabilities, which combines national reach with best-in-class technology, operational excellence and unmatched technical sales expertise,” says Hank Struik, Chief Executive Officer of LABSCO. “As the leader in the molecular and syndromic diagnosis of infectious diseases, BioFire is the perfect partner for LABSCO, and has demonstrated a commitment to excellence through their innovative FilmArray Technology line and focus on improving patient outcomes. Their innovative molecular diagnostics offer fits our exclusive clinical portfolio, which includes the industry’s leading technologies for Chemistry, Immunoassay, Hematology, Coagulation, Blood Gas and Point of Care diagnostics.”

“This strategic partnership with LABSCO furthers BioFire Diagnostics’ commitment to fight against infectious diseases, support antibiotic stewardship, improve patient care and reduce healthcare costs,” said Randy Rasmussen, bioMérieux Corporate Vice President of Molecular Biology and CEO of BioFire Diagnostics. “We chose LABSCO due to their lab focus, clinical sales expertise, customer intimacy and proven molecular track record in key market segments where BioFire has the potential to develop. We are confident this relationship will help drive further adoption of the FilmArray’s syndromic approach for the diagnosis of infectious diseases.”

FilmArray is a CE-marked and FDA-cleared multiplex PCR system that is easy to use, accurate and rapid. Using a single reagent or panel, it identifies the most common disease-causing organisms responsible for a syndrome, whether they are viruses, bacteria, fungi or parasites. FilmArray’s menu currently comprises three panels – respiratory, blood culture identification and gastrointestinal – all of which are CE-marked and FDA-cleared. Additionally, BioFire has submitted a de novo application to the FDA for its Meningitis-Encephalitis panel.

These are truly exciting times in healthcare with challenges driving the need for market leaders to think and act differently to best serve healthcare professionals. The new partnership between BioFire and LABSCO can offer solutions to help healthcare professionals overcome these challenges.

ABOUT LABSCO

LABSCO Delivers Superior Diagnostics, specializing in community hospital labs and POLs. LABSCO provides a best-in-class portfolio of laboratory solutions that improve lab efficiency and patient care by enhancing clinical, operational and financial outcomes.

LABSCO uniquely serves as: an exclusive sales agent with allies such as Siemens, Sysmex and BioFire, a specialty distributor for market-leading brands of ancillary capital equipment and a general distributor of private label and key brand partner supplies.

LABSCO sales force representatives are clinical laboratory experts in Chemistry, Immunoassay, Molecular, Hematology, Hemostasis, Blood Gas, Diabetes Care, Urinalysis, Point of Care, Lab Supplies and Lab Intelligence.

Learn more at LABSCO.com

ABOUT FRAZIER HEALTHCARE

Founded in 1991, Frazier Healthcare is a leading provider of venture and growth buyout capital to emerging healthcare service and biopharma companies. With over $2 billion under management across seven funds, Frazier Healthcare has invested in more than 150 companies across the entire developmental spectrum. From venture investments to leveraged recapitalizations, Frazier Healthcare has established itself among entrepreneurs and seasoned executives as a preferred partner to help create and grow successful healthcare companies.

For further information, please visit www.BioFireDx.com or www.biomerieux.com.